Kiniksa Pharmaceuticals (NASDAQ:KNSA) Given Outperform Rating at Wedbush

Wedbush reissued their outperform rating on shares of Kiniksa Pharmaceuticals (NASDAQ:KNSA - Free Report) in a research note published on Wednesday, Marketbeat.com reports. The firm currently has a $34.00 price target on the stock.

Separately, Citigroup started coverage on shares of Kiniksa Pharmaceuticals in a research note on Thursday, March 13th. They set a "buy" rating and a $40.00 target price on the stock. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Kiniksa Pharmaceuticals presently has an average rating of "Buy" and an average target price of $37.17.

Kiniksa Pharmaceuticals Stock Down 0.3 %

NASDAQ:KNSA traded down $0.07 on Wednesday, hitting $20.14. The stock had a trading volume of 273,614 shares, compared to its average volume of 462,592. Kiniksa Pharmaceuticals has a 52-week low of $16.87 and a 52-week high of $28.15. The stock has a market cap of $1.46 billion, a price-to-earnings ratio of -143.85 and a beta of 0.31. The business's 50-day simple moving average is $21.05 and its two-hundred day simple moving average is $21.45.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last announced its earnings results on Tuesday, February 25th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.06). Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The business had revenue of $122.50 million for the quarter, compared to the consensus estimate of $123.42 million. During the same quarter last year, the firm posted $0.35 earnings per share. The business's quarterly revenue was up 46.9% compared to the same quarter last year. As a group, equities research analysts anticipate that Kiniksa Pharmaceuticals will post -0.55 EPS for the current year.

Insiders Place Their Bets

In other Kiniksa Pharmaceuticals news, COO Eben Tessari sold 12,000 shares of the business's stock in a transaction that occurred on Monday, April 14th. The stock was sold at an average price of $20.48, for a total transaction of $245,760.00. Following the completion of the transaction, the chief operating officer now owns 77,363 shares in the company, valued at $1,584,394.24. The trade was a 13.43 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CAO Michael R. Megna sold 9,051 shares of the company's stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $22.45, for a total value of $203,194.95. Following the transaction, the chief accounting officer now directly owns 26,528 shares in the company, valued at approximately $595,553.60. This represents a 25.44 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 91,766 shares of company stock valued at $2,002,135 in the last three months. Corporate insiders own 54.57% of the company's stock.

Institutional Trading of Kiniksa Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. GAMMA Investing LLC lifted its holdings in Kiniksa Pharmaceuticals by 84.8% during the 1st quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock valued at $27,000 after buying an additional 568 shares in the last quarter. Lazard Asset Management LLC purchased a new stake in shares of Kiniksa Pharmaceuticals in the fourth quarter valued at approximately $61,000. KLP Kapitalforvaltning AS purchased a new stake in shares of Kiniksa Pharmaceuticals in the fourth quarter valued at approximately $158,000. Bellevue Group AG bought a new position in Kiniksa Pharmaceuticals in the fourth quarter worth approximately $160,000. Finally, Tower Research Capital LLC TRC increased its holdings in Kiniksa Pharmaceuticals by 117.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 8,483 shares of the company's stock worth $168,000 after purchasing an additional 4,575 shares during the period. Hedge funds and other institutional investors own 53.95% of the company's stock.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.